Draxis Pharma, the CMO division of Draxis Health Inc., recently received word from the FDA that its Montreal facilities passed inspection. FDA conducted inspections of all six production and quality systems at Draxis Pharma in January 2007. The inspection was conducted primarily with regard to two products manufactured on behalf of clients in the Draxis Pharma sterile lyophilization  production site. According to Draxis, there were no Form 483 Inspectional Observations issued during the evalu...